ALS Research at Risk from Proposed FY27 Budget Cuts
ARLINGTON, Virginia, United States, April 7, 2026 The ALS Association has issued a strong statement warning that the proposed...
ALS
Advertisement
Trethera Expands ALS Trial with MGH for TRE-515
LOS ANGELES, March 31, 2026 Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate...
XellSmart Secures Dual FDA, NMPA IND for MSA-P
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
ANQUR Trial Shows STMN2 Restoration in ALS Patients
CAMBRIDGE, Mass., Feb. 23, 2026 — QurAlis announced interim clinical results from its Phase 1/2 ANQUR study demonstrating that...
FDA Clears First-in-Class Vectorized Antibody ALS Trial With VTx-002
Amsterdam, The Netherlands, and Boston, MA — January 8, 2026 — VectorY Therapeutics announced that the U.S. Food and...
Advertisements
QurAlis Shows ALS Target Engagement in Phase 1 Trial
CAMBRIDGE, Massachusetts — QurAlis Corporation has announced topline Phase 1 proof-of-mechanism clinical data demonstrating clear target engagement in patients...
Elanco Leader Joins Neurizon to Boost ALS Drug Program
MELBOURNE, Australia – Nov. 26, 2025 — Neurizon Therapeutics (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech firm...
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
AB Science Secures €2.8 Million in Private Placement to Advance Clinical Pipeline
PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors,...
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Advertisement
